Keyword: AvroBio

Shares in Avrobio dropped after it reported results from the first three patients on its Fabry disease gene therapy, raising durability questions.

No fewer than five biotech IPOs debuted Thursday, raising more than $460 million and with more in the offing if underwriters take up further options.

The IPO would give Avrobio the means to trial gene therapies designed to supplant enzyme replacement therapies from Sanofi, Shire and Pfizer.

With the financing, Avrobio plans to push its pipeline through the clinic "as aggressively as possible."